Q1 2026 Bio Rad Laboratories Inc Earnings Call Transcript
Key Points
- Bio-Rad Laboratories Inc (BIO) reported Q1 results within their revenue guidance despite external pressures, showcasing effective management.
- The digital PCR product area continues to be a strategic differentiator, with ddPCR instrument revenue growing 24% over the prior year.
- The new QX700 platform is driving competitive wins and conversion from ddPCR, supported by an extensive assay menu and expanding publication base.
- Bio-Rad Laboratories Inc (BIO) is executing a clear agenda focused on improving agility, resiliency, and efficiency across the company.
- The Stilla acquisition is on track to be accretive by mid-year, contributing to both revenue growth and margin expansion.
- The ongoing conflict in the Middle East significantly reduced Q1 2026 revenues and is expected to be a headwind for revenue and margin for the full year.
- Academic demand remained constrained, particularly in the Americas, due to changes in funding, impacting the Life Science segment.
- The Clinical Diagnostics segment was adversely affected by geopolitical disruption in the Middle East, impacting both demand and logistics.
- Consolidated gross margin was slightly lower due to unfavorable manufacturing absorption, higher freight fuel surcharges, and foreign exchange impacts.
- The company adjusted its 2026 guidance due to ongoing challenges in the Middle East, projecting currency-neutral revenue growth to be between minus 3% and plus 0.5%.
Ladies and gentlemen, thank you for standing by. My name is Regina, and I will be your conference operator today. At this time, I would like to welcome everyone to Bio-Rad's first-quarter 2026 results conference call and webcast. (Operator Instructions)
I would now like to turn the conference over to Ruben Argueta, Bio-Rad's Head of Investor Relations. You may begin.
Thank you, Regina. Good afternoon, everyone, and thank you for joining us. My name is Ruben Argueta, Bio-Rad's new Head of IR. It's a pleasure to join the team and be with you here.
Today, we will review the financial results for the first quarter ended March 31, 2026, and provide an update on key business trends for Bharat.
With me on the call today are Norman Schwartz, our Chief Executive Officer; John DiVincenzo, President and Chief Operating Officer; and Roop Lakkaraju, Executive Vice President and Chief Financial Officer.
Before we begin our review, I would like to remind
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
